Craft

Personalis

Stock Price

$5.1

2024-10-29

Market Capitalization

$340.9 M

2024-10-29

Revenue

$69.6 M

FY, 2025

Personalis Summary

Company Summary

Overview
Personalis is a biotechnology company that specializes in cancer genomics. It develops the NeXT, a platform that offers tumor and normal tissue profiling to provide healthcare professionals with insights into a patient's cancer biology. The company also provides genome sequencing and data analysis services to support the development of cancer therapies.
Type
Public
Status
Active
Founded
2011
HQ
Fremont, CA, US | view all locations
Website
https://www.personalis.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Aaron Tachibana

    Aaron Tachibana, Chief Financial Officer and Chief Operating Officer

  • Christopher Hall

    Christopher Hall, Chief Executive Officer, President, and Director

  • Richard Chen

    Richard Chen, Senior Vice President R&D and Chief Medical Officer

  • Susan Moriconi

    Susan Moriconi, Vice President of People and Chief Human Resources Officer

Operating MetricsView all

Patents Issued

16
23.1%

FY, 2021

Facilities Leased (US), square feet

46K
47.1%

FY, 2021

LocationsView all

2 locations detected

  • Fremont, CA HQ

    United States

    6600 Dumbarton Circle

  • West Wickham, England

    United Kingdom

    Squires House, 205A High Street

Personalis Financials

Summary Financials

Revenue (Q1, 2026)
$15.5M
Gross profit (Q1, 2026)
$281.0K
Net income (Q1, 2026)
($30.0M)
Cash (Q1, 2026)
$73.6M
EBIT (Q1, 2026)
($32.2M)
Enterprise value
$298.3M

Footer menu